Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Klain

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Cancers|October 13, 2021
Advances in Functional Imaging of Differentiated Thyroid CancerMichele Klain, Emilia Zampella, Carmela Nappi, et al.
Life (Basel, Switzerland)|September 23, 2022
Initial Testing of an Approximated, Fast Calculation Procedure for Personalized Dosimetry in Radionuclide Therapy Based on Planar Whole-Body Scan and Monte-Carlo Specific Dose Rates from the <i>OpenDose</i> ProjectDavide Bianco, Carmela Nappi, Leandra Piscopo, et al.
Cancers|August 26, 2023
Efficacy of Empirical Radioiodine Therapy in Patients with Differentiated Thyroid Cancer and Elevated Serum Thyroglobulin without Evidence of Structural Disease: A Propensity Score AnalysisLeandra Piscopo, Emilia Zampella, Fabio Volpe, et al.
Frontiers in Medicine|August 6, 2019
Incremental Value of Sestamibi SPECT/CT Over Dual-Phase Planar Scintigraphy in Patients With Primary Hyperparathyroidism and Inconclusive UltrasoundRoberta Assante, Emilia Zampella, Emanuele Nicolai, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 24, 2025
External validation of a predictive model for post-treatment persistent disease by <sup>131</sup>I whole-body scintigraphy in patients with differentiated thyroid cancerCarmela Nappi, Rosario Megna, Emilia Zampella, et al.
Endocrine|June 13, 2020
Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancerMichele Klain, Emilia Zampella, Mariarosaria Manganelli, et al.
Current Oncology (Toronto, Ont.)|January 20, 2023
Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre StudyLeandra Piscopo, Fabio Volpe, Carmela Nappi, et al.
Clinical Endocrinology|March 5, 2002
Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset diseaseCarolina Di Somma, Rosario Pivonello, Sandro Loche, et al.
Medicine|October 20, 2017
Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapyBarbara Salvatore, Michele Klain, Emanuele Nicolai, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2006
Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal statusLibuse Tauchmanovà, Rosario Pivonello, Carolina Di Somma, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Cancers|October 13, 2021
Advances in Functional Imaging of Differentiated Thyroid CancerMichele Klain, Emilia Zampella, Carmela Nappi, et al.
Life (Basel, Switzerland)|September 23, 2022
Initial Testing of an Approximated, Fast Calculation Procedure for Personalized Dosimetry in Radionuclide Therapy Based on Planar Whole-Body Scan and Monte-Carlo Specific Dose Rates from the <i>OpenDose</i> ProjectDavide Bianco, Carmela Nappi, Leandra Piscopo, et al.
Cancers|August 26, 2023
Efficacy of Empirical Radioiodine Therapy in Patients with Differentiated Thyroid Cancer and Elevated Serum Thyroglobulin without Evidence of Structural Disease: A Propensity Score AnalysisLeandra Piscopo, Emilia Zampella, Fabio Volpe, et al.
Frontiers in Medicine|August 6, 2019
Incremental Value of Sestamibi SPECT/CT Over Dual-Phase Planar Scintigraphy in Patients With Primary Hyperparathyroidism and Inconclusive UltrasoundRoberta Assante, Emilia Zampella, Emanuele Nicolai, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 24, 2025
External validation of a predictive model for post-treatment persistent disease by <sup>131</sup>I whole-body scintigraphy in patients with differentiated thyroid cancerCarmela Nappi, Rosario Megna, Emilia Zampella, et al.
Endocrine|June 13, 2020
Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancerMichele Klain, Emilia Zampella, Mariarosaria Manganelli, et al.
Current Oncology (Toronto, Ont.)|January 20, 2023
Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre StudyLeandra Piscopo, Fabio Volpe, Carmela Nappi, et al.
Clinical Endocrinology|March 5, 2002
Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset diseaseCarolina Di Somma, Rosario Pivonello, Sandro Loche, et al.
Medicine|October 20, 2017
Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapyBarbara Salvatore, Michele Klain, Emanuele Nicolai, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2006
Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal statusLibuse Tauchmanovà, Rosario Pivonello, Carolina Di Somma, et al.
Pageof 8